News & Updates
Filter by Specialty:
Dupilumab trumps MTX, cyclosporine in paediatric AD
The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.
Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
Dupilumab-associated ocular surface disease less common in children, teens with AD
The incidence of ocular surface disease associated with dupilumab treatment for moderate-to-severe atopic dermatitis is lower in children and adolescents than that described in adults, suggests a retrospective review at a tertiary paediatric hospital in Singapore
Dupilumab-associated ocular surface disease less common in children, teens with AD
18 Jan 2025
Photosensitivity status in atopic dermatitis may change over time
Light sensitivity patterns vary in patients with atopic dermatitis (AD), reports a Scotland study, noting the significance of follow-up assessments because of potential shifts in disease spectrum over time.
Photosensitivity status in atopic dermatitis may change over time
07 Jan 2025
Corticosteroid phobia tied to poor treatment adherence in chronic hand eczema
Topical corticosteroid (TCS) phobia (TOPICOP) commonly exists among patients with chronic hand eczema (CHE) and often leads to poor treatment adherence, suggests a recent study.